[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"remote-ischemic-conditioning\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:remote-ischemic-conditioning":31},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,45,77,99],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":24,"briefSummary":26,"conditions":27,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100651578","evaluating-antiplatelet-and-physical-therapy-for-slowing-progression-in-mild-moyamoya-disease-100651578",false,"NCT07762547","Evaluating Antiplatelet and Physical Therapy for Slowing Progression in Mild Moyamoya Disease.","Study on the Effects of Pharmacological and Physical Therapy in Delaying the Progression of Moyamoya Disease (Moyamoya Syndrome) : Randomized Controlled Study","MOUNT-EASE","History of any form of intracranial hemorrhage, including subarachnoid hemorrhage, intracerebral hemorrhage, intraventricular hemorrhage, etc.; history of symptomatic ischemic stroke; frequent transient ischemic attacks (TIAs) before enrollment, defined as ≥3 episodes within 7 days; or history of epileptic seizures.\n\nConcomitant cerebrovascular diseases that may significantly affect perioperative risk or outcome assessment, such as intracranial aneurysms requiring concomitant treatment, cerebral arteriovenous malformations, arteriovenous fistulas, or other relevant cerebrovascular lesions.\n\nHistory of severe traumatic brain injury, brain tumor, encephalitis, meningitis, or other inflammatory diseases of the central nervous system; other major intracranial diseases; any prior invasive intracranial treatment; or history of cranial radiotherapy.\n\nPlanned cerebral revascularization surgery within 3 months. Severe cardiac dysfunction (left ventricular ejection fraction \\\u003C50% or New York Heart Association \\[NYHA\\] class III-IV), hepatic dysfunction (alanine aminotransferase \\[ALT\\] or aspartate aminotransferase \\[AST\\] \\>2 times the upper limit of normal), or renal dysfunction (serum creatinine \\>1.5 times the upper limit of normal); major systemic diseases such as unstable angina, acute coronary syndrome, asthma, or chronic obstructive pulmonary disease (COPD); severe noncardiovascular comorbidities with an expected survival of \\\u003C1 year; or any other serious comorbidity considered by the investigator to significantly increase study-related risk.\n\nContraindications to aspirin, including:\n\n1. Known allergy to aspirin;\n2. Severe renal dysfunction (serum creatinine \\>1.5 times the upper limit of normal) or severe hepatic dysfunction (ALT or AST \\>2 times the upper limit of normal);\n3. Severe heart failure (NYHA class III-IV);\n4. Coagulation disorders or a history of systemic bleeding;\n5. History of thrombocytopenia or neutropenia;\n6. History of drug-induced hematologic disorders or hepatic injury;\n7. White blood cell count \\\u003C2×10⁹\u002FL or platelet count \\\u003C100×10⁹\u002FL;\n8. History of gastrointestinal bleeding within 3 months before enrollment, or a documented history of gastric ulcer or gastritis;\n9. Any other contraindication to aspirin.\n\nContraindications to remote ischemic conditioning (RIC), including:\n\n1. Peripheral vascular disease of the upper or lower extremities, particularly significant stenosis or occlusion of the brachial, ulnar, or radial arteries, or any condition considered by the investigator to make upper-arm cuff inflation for RIC unsuitable;\n2. Conditions that may affect the safety of upper-limb RIC, including but not limited to severe skin or soft-tissue infection or injury, marked lymphedema, arteriovenous fistula or dialysis fistula, recent deep venous thrombosis, or inability to tolerate upper-arm cuff inflation as judged by the investigator, such as severe pain or recurrent subcutaneous bleeding;\n3. Known allergy to the RIC device or any of its component materials. Requirement for aspirin and\u002For other antiplatelet therapy because of diseases other than moyamoya disease, such as systemic, circulatory, or hematologic disorders; or continuous use of other antiplatelet agents for ≥5 days before enrollment, with the last dose administered within 10 days before enrollment.\n\nRequirement for anticoagulant therapy, including conditions such as atrial fibrillation, prosthetic heart valves, known or suspected endocarditis, venous thrombosis, or other diseases requiring anticoagulation; or use of heparin or oral anticoagulants within 10 days before enrollment.\n\nPregnancy, suspected pregnancy (defined as a positive pregnancy test in a woman of childbearing potential who has not used effective contraception), or breastfeeding.\n\nConditions that may interfere with completion of key follow-up assessments, such as severe cognitive impairment or psychiatric disorders resulting in inability to cooperate with study evaluations, or a clear expectation that follow-up cannot be completed.\n\nCurrent participation in another interventional clinical trial that, in the investigator's judgment, may interfere with assessment of the study outcomes","ALL","18 Years","70 Years",{"count":21,"type":22},724,"ESTIMATED","INTERVENTIONAL",[25],"NA","Moyamoya disease (MMD) is a chronic occlusive cerebrovascular disease characterized by progressive stenosis or occlusion at the terminal portion of the internal carotid artery, with formation of an abnormal vascular network at the base of the brain. Moyamoya syndrome (MMS) has the same cerebrovascular imaging and clinical manifestations as moyamoya disease, but it is accompanied by other systemic comorbidities. Moyamoya disease and moyamoya syndrome are collectively referred to as moyamoya-like cerebrovascular disease. They are highly prevalent in East Asia, and China has a large patient population. In 2018, the incidence was 1.6 per 100,000 person-years, and the disease is a major cause of stroke in children, adolescents, and young adults \\[1\\]. This group of diseases often causes severe complications such as stroke and cognitive impairment, leading to poor prognosis and reduced ability to live independently \\[2\\]. Among patients who do not receive effective treatment, the risk of severe neurological deficit or death is as high as 75%, and approximately 60% of patients with moyamoya disease develop cognitive impairment \\[3\\]. Therefore, moyamoya disease (moyamoya syndrome) is a major health problem that seriously affects the health of the Chinese population.\n\nAt present, several urgent problems remain in the clinical diagnosis and treatment of moyamoya disease (moyamoya syndrome). First, the epidemiological characteristics and disease susceptibility of this condition in the Chinese population are not yet fully clear. Second, reliable clinical assessment tools and standardized risk prediction models for moyamoya disease are lacking, and there is still no clear basis for identifying which patients need timely intervention. Third, a systematic precision treatment pathway for moyamoya disease has not yet been established, and high-quality evidence is still lacking regarding the role of pharmacological and physical therapy in delaying disease progression. Therefore, systematic research to clarify the efficacy of different treatment approaches in moyamoya disease is of great significance for promoting the establishment of an integrated diagnostic and therapeutic system for this disease.\n\n\\[Add a paragraph introducing ischemic conditioning and its role in stroke and MMD.\\] Systematic treatment is an important means to improve the prognosis of moyamoya disease. Current major treatment options include revascularization surgery and pharmacological therapy. Previous studies have shown that revascularization surgery can improve cerebral blood flow and reduce the risk of stroke; however, for asymptomatic or early-stage patients, surgery is not the only option \\[4\\]. In terms of pharmacological therapy, nonsurgical treatments such as antiplatelet therapy and intensive lipid-lowering therapy may delay disease progression, but high-quality clinical evidence remains lacking. In addition, emerging physical therapies such as ischemic conditioning have been shown to improve the tolerance of brain tissue to ischemia and have demonstrated potential therapeutic value in patients with stroke \\[5\\]. However, the safety and efficacy of these treatment approaches in patients with moyamoya disease require further study and validation.\n\nTherefore, this study proposes to conduct a multicenter, prospective randomized controlled clinical trial to systematically evaluate the efficacy and safety of aspirin therapy and ischemic conditioning therapy in delaying the progression of moyamoya disease, and to provide evidence-based support for nonsurgical treatment strategies for patients with moyamoya disease.\n\n\\[The following content was moved from the study rationale section and should be integrated with the research background.\\] Even when patients with moyamoya disease (moyamoya syndrome) have not yet developed definite symptoms of cerebral infarction, their cerebral hemodynamics may already be in a compensated or critical state. They are often prone to nonspecific symptoms such as headache and dizziness, subjective cognitive decline, and TIA attacks, and they have a potential risk of progression to symptomatic stroke. Microembolus formation and vascular endothelial dysfunction may further reduce flow reserve and aggravate hypoperfusion, thereby leading to adverse events. For such mildly affected patients, early intervention has important clinical value for delaying disease progression and preventing cerebrovascular events.\n\nAspirin irreversibly inhibits cyclooxygenase-1 and blocks thromboxane A2 production, thereby inhibiting platelet aggregation. In the pathological process of moyamoya disease (moyamoya syndrome), microcirculatory changes and vascular intimal injury may activate platelets and promote microthrombus formation, which may aggravate ischemia-induced stroke. Therefore, aspirin may reduce the risk of ischemic events by inhibiting platelet aggregation. Ischemic conditioning is a noninvasive physical therapy that activates systemic endogenous protect",[28,29,30,31],"Moyamoya Disease","Moyamoya Syndrome","Aspirin","Remote Ischemic Conditioning","NOT_YET_RECRUITING","2026-08-09",{"date":35,"type":36},"2026-08-13","ACTUAL",{"date":38,"type":22},"2026-07-15",{"date":40,"type":22},"2030-02-28",{"name":42,"class":43},"Beijing Tiantan Hospital","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":23,"phases":57,"briefSummary":58,"conditions":59,"keywords":64,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":68,"startDateStruct":70,"completionDateStruct":72,"leadSponsor":74,"locationsCount":76},"100570936","remote-ischemic-conditioning-for-non-proliferative-diabetic-retinopathy-100570936","NCT06713720","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy","Remote Ischemic Conditioning for Non-Proliferative Diabetic Retinopathy (RIC-NPDR)","RIC-NPDR","Inclusion Criteria:\n\n* Age between 40 and 80 years.\n* Diagnosed with Type 2 diabetes mellitus.\n* Diagnosed with mild to moderate non-proliferative diabetic retinopathy (NPDR) with a DR Severity Score (DRSS) grade of 20-47D.\n* Capable of performing daily activities independently.\n* Willing and able to provide informed consent.\n\nExclusion Criteria:\n\n* Presence of diabetic macular edema (macular thickness \\> 250 μm).\n* Significant eye diseases affecting evaluation, such as high myopia, severe cataract, corneal leucoma, glaucoma, retinal detachment, retinal vein occlusion, congenital eye diseases, ocular tumors, or severe infection.\n* History of ocular laser or intraocular surgery.\n* Poor imaging quality due to refractive media opacity.\n* Contraindication to fluorescein fundus angiography.\n* Unstable blood glucose (HbA1c ≥ 8.0%) despite oral antidiabetic drugs.\n* Severe diabetes complications within the past 6 months.\n* Severe, sustained hypertension (systolic ≥ 180 mmHg or diastolic ≥ 110 mmHg).\n* Body mass index (BMI) ≥ 28 kg\u002Fm².\n* Hepatic or renal insufficiency: Alanine aminotransferase or aspartate aminotransferase \\> 2 times the upper limit of normal. Estimated glomerular filtration rate (eGFR) \\\u003C 60 mL\u002Fmin\u002F1.73m². Urine albumin\u002Fcreatinine ratio ≥ 30 mg\u002Fg.\n* Myocardial infarction within the past 6 months.\n* Neurological diseases such as Alzheimer's, Parkinson's, cerebrovascular disease, intracranial tumor, cerebrovascular malformation, or aneurysm.\n* Contraindications to RIC, including one-sided subclavian artery stenosis, upper limb injuries or vascular diseases, or limb deformities.\n* Severe systemic diseases, such as malignant tumors with a life expectancy of less than 24 months.\n* Known pregnancy or breastfeeding.\n* Participation in other experimental clinical studies.\n* Any other conditions deemed unsuitable by the investigator.","40 Years","80 Years",{"count":56,"type":22},68,[25],"The goal of this clinical trial is to evaluate whether remote ischemic conditioning (RIC) is a safe and effective treatment for non-proliferative diabetic retinopathy (NPDR) in adults aged 40-80 years with type 2 diabetes. The study aims to address the limitations of current treatments for NPDR by using RIC, a technique involving repeated cycles of ischemia and hypoxia stimulation to activate protective mechanisms against retinal damage.\n\nThe main questions it aims to answer are:\n\nDoes RIC improve the Diabetic Retinopathy Severity Score (DRSS) after one year of treatment? Does RIC reduce the incidence of vision-threatening proliferative diabetic retinopathy (PDR)? What are the changes in retinal neurovascular unit parameters, visual acuity, and retinal oxygen saturation after RIC treatment?\n\nParticipants will:\n\nUndergo RIC therapy using a specialized device on both upper limbs (or a placebo intervention for the control group) for 1 year.\n\nComplete 5 cycles of RIC or placebo treatment twice daily, 5 days per week. Receive routine care for diabetic retinopathy as per clinical guidelines.\n\nKey outcome measures:\n\nPrimary outcome: Change in DRSS from baseline after one year. Secondary outcomes: Incidence of PDR, changes in visual acuity, retinal neurovascular unit measures, retinal oxygen saturation, and serum biomarkers (e.g., VEGF, CRP, IL-6).\n\nThis randomized, double-blind, placebo-controlled trial aims to recruit 68 participants to ensure 60 complete the study, accounting for a 13% dropout rate. The findings are expected to provide insights into RIC as a novel intervention for NPDR, reducing blindness risk and supporting future large-scale trials.",[60,61,31,62,63],"Diabetic Retinopathy","Non-Proliferative Diabetic Retinopathy","Diabetes Mellitus, Type 2","Randomized Controlled Trial",[61,60,65,31,63],"Retinal Neurovascular Unit","RECRUITING","2025-06-22",{"date":69,"type":36},"2025-06-26",{"date":71,"type":36},"2025-04-20",{"date":73,"type":22},"2026-05-31",{"name":75,"class":43},"Xuxiang Zhang, MD",2,{"id":78,"slug":79,"hasResults":11,"nctId":80,"briefTitle":81,"officialTitle":82,"acronym":4,"eligibilityCriteria":83,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":84,"targetDuration":4,"studyType":23,"phases":86,"briefSummary":87,"conditions":88,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":90,"lastUpdatePostDateStruct":91,"startDateStruct":93,"completionDateStruct":94,"leadSponsor":96,"locationsCount":98},"100586847","efficacy-of-remote-ischemic-conditioning-in-preventing-post-stroke-depression-100586847","NCT06920706","Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression","Efficacy of Remote Ischemic Conditioning in Preventing Post-Stroke Depression: A Multicenter, Randomized, Double-Blind, Sham-Controlled Clinical Trial","Inclusion Criteria:\n\n* Patient age≥18 years;\n* No gender preference;\n* Diagnosed with acute ischemic stroke;\n* From onset to treatment ≤48 h;\n* 6≤ NIHSS scores ≤25;\n* Premorbid mRS ≤1;\n* Signed informed consent.\n\nExclusion Criteria:\n\n* Baseline HAMD-24 scores ≥8;\n* Infarction area overlapped with the area where the DTI-ALPS index is calculated;\n* A history of severe mental illness such as depression, bipolar disorder, and schizophrenia;\n* A history of mental disorders caused by other organic diseases, such as post-Parkinson depression;\n* Participants with cognitive impairment, disturbance of consciousness, severe hearing impairment, or aphasia who were unable to cooperate with the assessment;\n* A history of autoimmune diseases (such as multiple sclerosis, neuromyelitis optica spectrum disorders, systemic lupus erythematosus, etc.), malignant tumors, or obstructive sleep apnea hypopnea syndrome;\n* Intracranial tumor, arteriovenous malformation, or aneurysm;\n* Uncontrolled severe hypertension (systolic pressure \\>180mmHg or diastolic pressure \\>110 mmHg after drug treatment) ;\n* Subclavian artery stenosis≥50% or subclavian steal syndrome;\n* Any contraindication for remote ischemic adaptation: the upper limb has serious soft tissue injury, fracture or vascular injury, distal upper limb perivascular lesions, etc.;\n* Severe coagulation dysfunction, platelet count \\\u003C 100×10\\^9\u002FL, cardiac dysfunction (NYHA class Ⅲ or above), hepatic dysfunction (aspartate aminotransferase and\u002For alanine aminotransferase \\> 3 times the upper limit of normal), or renal dysfunction (serum creatinine \\> 265μmol\u002FL);\n* Any contraindication for magnetic resonance imaging: metal implants, claustrophobia, etc.;\n* Women known to be pregnant or lactating, or have a positive pregnancy test;\n* Participating in other clinical trials within three months;\n* Participants not suitable for this clinical studies considered by researcher.",{"count":85,"type":22},240,[25],"Post-stroke depression (PSD) is characterized primarily by low mood and loss of interest following a stroke. It is one of the most common and serious complications of stroke, with an incidence of 11% to 41% within two years post-stroke. PSD significantly impacts stroke prognosis, not only hindering neurological recovery but also increasing clinical disability and mortality rates, thereby imposing substantial economic and psychological burdens on families and society. Therefore, preventing PSD is crucial for stroke rehabilitation.\n\nClinical trials have demonstrated that preventive antidepressant treatment can reduce PSD incidence and improve clinical outcomes; however, controversies remain regarding the timing, methods, and safety. Meanwhile, preventive psychological therapy faces challenges in implementation due to effectiveness, accessibility, and cost-effectiveness.\n\nRemote ischemic preconditioning (RIC) is a non-invasive, cost-effective, and non-pharmacological intervention. By modulating small molecules in the peripheral and central nervous systems through transient, periodic limb blood flow restriction and reperfusion, RIC reverses neurobiological changes and demonstrates neuroprotective potential in various neurological diseases. Recently, a study showed that RIC is safe and effective in preventing PSD; however, the sample size is small and the specific mechanisms remain unclear. Therefore, this study aims to further explore the role and mechanisms of RIC in PSD prevention.",[89,31],"Post-stroke Depression","2025-04-02",{"date":92,"type":36},"2025-04-10",{"date":92,"type":22},{"date":95,"type":22},"2026-12-31",{"name":97,"class":43},"Xuanwu Hospital, Beijing",5,{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":105,"eligibilityCriteria":106,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":107,"targetDuration":4,"studyType":23,"phases":109,"briefSummary":110,"conditions":111,"keywords":4,"overallStatus":66,"whyStopped":4,"lastUpdateSubmitDate":114,"lastUpdatePostDateStruct":115,"startDateStruct":117,"completionDateStruct":119,"leadSponsor":121,"locationsCount":44},"100526959","safety-and-efficacy-of-remote-ischemic-conditioning-for-patients-taking-off-pump-coronary-artery-bypass-grafting-100526959","NCT06141525","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting","Safety and Efficacy of Remote Ischemic Conditioning for Patients Taking Off-pump Coronary Artery Bypass Grafting (IMPROVE): A National, Multi-center, Randomized, Controlled, Open-label, Blinded-endpoint Trial","IMPROVE","Inclusion Criteria:\n\n* Diagnosed with coronary artery disease and require off-pump CABG surgery.\n* Between 18 and 75 years old;\n* Normal left ventricular systolic function (ejection fraction \\>40%) and left ventricular end-diastolic internal diameter (\\\u003C60 mm) in the cardiac ultrasound tests;\n* No or mild heart valve and great vessel abnormalities which do not require surgical intervention;\n* Participants or their authorized relatives agree to participate in the clinical trial and sign the informed consent.\n\nExclusion Criteria:\n\n* Severe tissue injuries.\n* Myalgia, fractures and other peripheral vascular lesions.\n* Bypass graft being the radial artery.\n* Stenosis or severe malformations of the subclavian, jugular and femoral arteries and veins.\n* Previous vagus nerve trunk dissection or vagus nerve block surgery.\n* Other surgical operations at the same time.\n* Patients with pre-existing severe cardiac insufficiency, acute coronary syndromes, malignant hypertension and cardiogenic shock.\n* Severe coagulation abnormality or severe anemia.\n* Severe mental disorder.\n* Malignant tumors.\n* Pregnant or lactating.\n* Increased risk of treatment for patients, according to investigators.\n* Refuse to sign the informed consent form.",{"count":108,"type":22},648,[25],"Remote ischemic conditioning (RIC) is the process of repeated ischemia and reperfusion in the peripheral vessels, which is proved in reducing IRI in vital organs. This IMPROVE trial plans to enroll 648 patients who are diagnosed with coronary artery disease and are going to take off-pump CABG in five centers in China, to access whether RIC can and improve short-term prognosis.",[112,31,113],"Coronary Artery Bypass Grafting","Ischemia-Reperfusion Injury","2024-07-10",{"date":116,"type":36},"2024-07-12",{"date":118,"type":36},"2023-11-22",{"date":120,"type":22},"2029-03-31",{"name":122,"class":43},"First Affiliated Hospital Xi'an Jiaotong University"]